{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:39:49Z","timestamp":1791362389527,"version":"4.3.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2021-I2M-1\u2013015"],"award-info":[{"award-number":["2021-I2M-1\u2013015"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2022-I2M-1\u2013008"],"award-info":[{"award-number":["2022-I2M-1\u2013008"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2022-I2M-2-002"],"award-info":[{"award-number":["2022-I2M-2-002"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972400"],"award-info":[{"award-number":["81972400"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202962"],"award-info":[{"award-number":["82202962"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010270","name":"Capital Health Research and Development of Special Fund","doi-asserted-by":"publisher","award":["2022-1-4021"],"award-info":[{"award-number":["2022-1-4021"]}],"id":[{"id":"10.13039\/501100010270","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["020"],"award-info":[{"award-number":["020"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFE0200800"],"award-info":[{"award-number":["2022YFE0200800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.canlet.2023.216300","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T11:29:15Z","timestamp":1688470155000},"page":"216300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["TIGIT immune checkpoint blockade enhances immunity of human peripheral blood NK cells against castration-resistant prostate cancer"],"prefix":"10.1016","volume":"568","author":[{"given":"Fangming","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianli","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianlin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiya","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nianzeng","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2023.216300_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA. Cancer J. Clin."},{"key":"10.1016\/j.canlet.2023.216300_bib2","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2017.7248","article-title":"The diagnosis and treatment of prostate cancer: a Review","volume":"317","author":"Litwin","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.canlet.2023.216300_bib3","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2023.216300_bib4","article-title":"Allogeneic expanded human peripheral NK cells control prostate cancer growth in a preclinical mouse model of castration-resistant prostate cancer","volume":"2022","author":"Wang","year":"2022","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.canlet.2023.216300_bib5","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1038\/emm.2017.42","article-title":"Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy","volume":"49","author":"Kwon","year":"2017","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.canlet.2023.216300_bib6","first-page":"55","article-title":"Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more, Semin","volume":"31","author":"Chiossone","year":"2017","journal-title":"Immunol"},{"key":"10.1016\/j.canlet.2023.216300_bib7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nri3799","article-title":"Balancing natural killer cell activation through paired receptors","volume":"15","author":"Martinet","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2023.216300_bib8","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2023.216300_bib9","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.trecan.2020.02.022","article-title":"Turning cold into hot: firing up the tumor microenvironment","volume":"6","author":"Duan","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.canlet.2023.216300_bib10","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold tumors: a therapeutic challenge for immunotherapy","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2023.216300_bib11","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-018-0085-8","article-title":"A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments","volume":"24","author":"Barry","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2023.216300_bib12","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2023.216300_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.901","article-title":"Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumor efficacy against castration-resistant prostate cancer","volume":"12","author":"Wang","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.canlet.2023.216300_bib14","doi-asserted-by":"crossref","first-page":"W98","DOI":"10.1093\/nar\/gkx247","article-title":"GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses","volume":"45","author":"Tang","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.canlet.2023.216300_bib15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/80859","article-title":"Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells","volume":"1","author":"Jiang","year":"2000","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2023.216300_bib16","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1073\/pnas.0712310105","article-title":"JNK MAP kinase activation is required for MTOC and granule polarization in NKG2D-mediated NK cell cytotoxicity","volume":"105","author":"Li","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2023.216300_bib17","doi-asserted-by":"crossref","first-page":"6329","DOI":"10.1073\/pnas.0611655104","article-title":"Many NK cell receptors activate ERK2 and JNK1 to trigger microtubule organizing center and granule polarization and cytotoxicity","volume":"104","author":"Chen","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2023.216300_bib18","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1182\/blood-2007-03-079699","article-title":"Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells","volume":"110","author":"Ong","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2023.216300_bib19","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1126\/science.1103478","article-title":"Natural killer cell signaling pathways","volume":"306","author":"Vivier","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.canlet.2023.216300_bib20","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1128\/MCB.24.6.2332-2343.2004","article-title":"Inhibition of the Jun N-terminal protein kinase pathway by SHIP-1, a lipid phosphatase that interacts with the adaptor molecule Dok-3","volume":"24","author":"Robson","year":"2004","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2023.216300_bib21","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0092-8674(00)80337-2","article-title":"Deletion of SHIP or SHP-1 reveals two distinct pathways for inhibitory signaling","volume":"90","author":"Ono","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2023.216300_bib22","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.euo.2021.09.006","article-title":"Epidemiology and prevention of prostate cancer","volume":"4","author":"Gandaglia","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.canlet.2023.216300_bib23","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.apsb.2021.07.016","article-title":"Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8+ T cell-mediated ferroptosis in castration-resistant prostate cancer","volume":"12","author":"Zhou","year":"2022","journal-title":"Acta Pharm. Sin. B."},{"key":"10.1016\/j.canlet.2023.216300_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1021870","article-title":"Editorial: immunotherapy for Prostate Cancer - turning the immunological desert into an oasis of hope","volume":"12","author":"Galustian","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2023.216300_bib25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2023.216300_bib26","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.3390\/cancers13174263","article-title":"Inhibitory receptors and immune checkpoints regulating natural killer cell responses to cancer","volume":"13","author":"Buckle","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2023.216300_bib27","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41423-019-0206-4","article-title":"Human NK cells: surface receptors, inhibitory checkpoints, and translational applications","volume":"16","author":"Sivori","year":"2019","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.canlet.2023.216300_bib28","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1172\/JCI123955","article-title":"Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells","volume":"129","author":"Kamiya","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2023.216300_bib29","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","article-title":"Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells","volume":"175","author":"Andr\u00e9","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2023.216300_bib30","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jaci.2016.04.025","article-title":"Identification of a subset of human natural killer cells expressing high levels of programmed death 1: a phenotypic and functional characterization","volume":"139","author":"Pesce","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.canlet.2023.216300_bib31","article-title":"Tim-3 blockade elicits potent anti-multiple myeloma immunity of natural killer cells","volume":"12","author":"Jiang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2023.216300_bib32","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1182\/blood-2011-11-392951","article-title":"Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity","volume":"119","author":"Ndhlovu","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2023.216300_bib33","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2011-06-360321","article-title":"Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9","volume":"119","author":"Gleason","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2023.216300_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2017.04.001","article-title":"Contribution of inhibitory receptor TIGIT to NK cell education","volume":"81","author":"He","year":"2017","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.canlet.2023.216300_bib35","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2023.216300_bib36","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1158\/1078-0432.CCR-20-0575","article-title":"IL15 stimulation with TIGIT blockade reverses CD155-mediated NK-Cell dysfunction in melanoma","volume":"26","author":"Chauvin","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2023.216300_bib37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/pros.10290","article-title":"Molecular characterization of human prostate carcinoma cell lines","volume":"57","author":"van Bokhoven","year":"2003","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2023.216300_bib38","doi-asserted-by":"crossref","first-page":"17858","DOI":"10.1073\/pnas.0903474106","article-title":"The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity","volume":"106","author":"Stanietsky","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2023.216300_bib39","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/blood-2007-09-077438","article-title":"Human natural killer cells","volume":"112","author":"Caligiuri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2023.216300_bib40","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/CJI.0b013e318182de23","article-title":"Natural killer cells in innate immunity and cancer","volume":"31","author":"Becknell","year":"2008","journal-title":"J. Immunother."},{"key":"10.1016\/j.canlet.2023.216300_bib41","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s00262-017-2031-x","article-title":"Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions","volume":"66","author":"Xu","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2023.216300_bib42","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/cdd.2012.141","article-title":"Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells","volume":"20","author":"Liu","year":"2013","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.canlet.2023.216300_bib43","doi-asserted-by":"crossref","first-page":"17647","DOI":"10.1074\/jbc.M114.572420","article-title":"T-cell immunoglobulin and ITIM domain (TIGIT) receptor\/poliovirus receptor (PVR) ligand engagement suppresses interferon-\u03b3 production of natural killer cells via \u03b2-arrestin 2-mediated negative signaling","volume":"289","author":"Li","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2023.216300_bib44","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2023.216300_bib45","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2023.216300_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.699895","article-title":"TIGIT, the next step towards successful combination immune checkpoint therapy in cancer","volume":"12","author":"Ge","year":"2021","journal-title":"Front. Immunol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383523002513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383523002513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:10:05Z","timestamp":1759594205000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383523002513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":46,"alternative-id":["S0304383523002513"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2023.216300","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TIGIT immune checkpoint blockade enhances immunity of human peripheral blood NK cells against castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2023.216300","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"216300"}}